Shares of Acadia Pharmaceuticals (ACAD) popped over 25 percent this week after an FDA panel voted in favor of approving its drug for Parkinson's disease psychosis. Despite the pop, the company's stock still trades at nearly half of where it was last summer. Michael Kramer, portfolio manager at Mott Capital at Covestor, says the corner has been turned and it could soon regain those heights with a potentially favorable outcome from the FDA in early May. Kramer added that the shares could see an additional surge because 'a lot of people got short the stock ahead of this panel thinking it would ultimately not get a favorable outcome.' Kramer is also bullish on Alkermes (ALKS) , which saw its stock halved in January when its depression drug disappointed in a trial.
More from Video
One Tweet Pulls the Rug Out From Under the Indexes
Despite the president's promise of no stimulus until after Nov. 3, there are no signs yet that this is the sort of correlated selling that leads to a deep correction.
A Technical Look at the New Dow Jones Industrial Average
Salesforce, Amgen and Honeywell will give a lift to the DJIA going forward.
Conagra Brands Looks Tastier After Its Upgrade to Buy
CAG has hung onto the bulk of its recent gains, and could rise to the $50 area, according to the charts and indicators.
Biogen Bulls Get a Lift From Quant Upgrade and Strengthening Charts
Breaking down an approach to the long side of this biotech stock.
Is Renewable Energy the Defensive Stock Opportunity You're Missing
AMSC CEO discusses that and China challenges.
Real Money's message boards are strictly for the open exchange of investment ideas among registered users. Any discussions or subjects off that topic or that do not promote this goal will be removed at the discretion of the site's moderators. Abusive, insensitive or threatening comments will not be tolerated and will be deleted. Thank you for your cooperation.
If you have questions, please contact us here.